AI Article Synopsis
- Alopecia areata (AA) is an autoimmune disease affecting hair growth, and efalizumab, a therapy for psoriasis, was tested for its effects on AA.
- The study involved 62 patients over three 12-week periods, comparing efalizumab to a placebo with a focus on hair regrowth and safety.
- Results showed no significant benefits from efalizumab, with both groups experiencing a low 8% response rate for hair regrowth, indicating it was not effective in this small trial.
Article Abstract
Background: Alopecia areata (AA) is a T-cell-mediated autoimmune disease. Efalizumab is a T-cell-targeted therapy approved for the treatment of psoriasis.
Objective: To assess the efficacy and safety of efalizumab in the treatment of moderate-to-severe AA.
Methods: Sixty-two patients were enrolled into this phase II, placebo-controlled trial. The trial consisted of three 12-week periods-a double-blind treatment period, an open-label efalizumab treatment period, and a safety follow-up.
Results: There were no statistical differences between treatment groups in percent hair regrowth, quality-of-life measures, or changes in biologic markers of disease severity after 12 or 24 weeks. In both groups, there was an approximately 8% response rate for hair regrowth (at 12 weeks). Efalizumab was well tolerated.
Limitations: Numbers were too small for certain analyses.
Conclusion: A 3- to 6-month trial of efalizumab was not effective in promoting hair regrowth in this small cohort of patients with moderate-to-severe AA.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jaad.2007.10.645 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!